A detailed history of Black Rock Inc. transactions in Greenwich Life Sciences, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 308,909 shares of GLSI stock, worth $4.31 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
308,909
Previous 56,459 447.14%
Holding current value
$4.31 Million
Previous $1.13 Million 373.87%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$12.07 - $19.04 $3.05 Million - $4.81 Million
252,450 Added 447.14%
308,909 $5.33 Million
Q1 2024

May 10, 2024

SELL
$8.31 - $20.32 $5,725 - $14,000
-689 Reduced 1.21%
56,459 $1.13 Million
Q4 2023

Feb 13, 2024

BUY
$7.77 - $12.3 $8,997 - $14,243
1,158 Added 2.07%
57,148 $601,000
Q3 2023

Nov 13, 2023

SELL
$8.41 - $10.66 $13,329 - $16,896
-1,585 Reduced 2.75%
55,990 $494,000
Q2 2023

Aug 11, 2023

BUY
$9.58 - $13.2 $7,884 - $10,863
823 Added 1.45%
57,575 $555,000
Q1 2023

May 12, 2023

BUY
$12.12 - $20.8 $70,659 - $121,264
5,830 Added 11.45%
56,752 $782,000
Q4 2022

Feb 13, 2023

BUY
$9.04 - $16.88 $1,003 - $1,873
111 Added 0.22%
50,922 $774,000
Q3 2022

Nov 14, 2022

SELL
$7.81 - $12.02 $1,874 - $2,884
-240 Reduced 0.47%
50,811 $462,000
Q2 2022

Aug 12, 2022

SELL
$7.14 - $20.36 $1.32 Million - $3.77 Million
-185,204 Reduced 78.39%
51,051 $433,000
Q1 2022

May 12, 2022

SELL
$16.3 - $24.65 $27,775 - $42,003
-1,704 Reduced 0.72%
236,255 $4.64 Million
Q4 2021

Feb 10, 2022

BUY
$21.76 - $39.43 $437,484 - $792,740
20,105 Added 9.23%
237,959 $5.79 Million
Q3 2021

Nov 09, 2021

BUY
$38.65 - $46.11 $4,096 - $4,887
106 Added 0.05%
217,854 $8.51 Million
Q2 2021

Aug 11, 2021

BUY
$31.24 - $53.6 $6.8 Million - $11.7 Million
217,748 New
217,748 $9.79 Million

Others Institutions Holding GLSI

About Greenwich LifeSciences, Inc.


  • Ticker GLSI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,848,200
  • Market Cap $179M
  • Description
  • Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...
More about GLSI
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.